Concord Drugs Ltd — Others, 01-08-2025: AGM/EGM

Concord Drugs Limited's Extra-Ordinary General Meeting concluded with shareholders approving all three key resolutions. These include a significant increase in the company's authorized capital, crucial for future expansion. Shareholders also gave their assent to issue equity shares and warrants on a preferential basis to both promoter and non-promoter groups. This strategic move enables the company to raise vital capital, reinforcing its financial position and supporting its growth initiatives, reflecting strong investor backing for Concord Drugs' forward path.